The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACB, ECHO, EPAY, HMTV, MYOK, NVDA, PFIE, TGE, TU Downgrades: BIIB, HBB, KEQU, MGYR, OBCI, OLP, PTMN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
The Dow Jones Industrial Average trades lower over fears on Wall Street of slowing global growth.
Biogen's board approves a share buyback program days after revealing a phase III trial of a promising Alzheimer's drug is being shelved.
Stocks are higher Thursday with the Dow up on strength in Apple.
Biogen shares are plunging almost 30% Thursday. Is this a screaming buy opportunity or a giant red flag?
Biogen shares plunge Thursday, wiping nearly $20 billion in value from the biotech group, after it dropped a late-stage trial for a key Alzheimer's disease drug.
All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.
Jim Cramer weighs in on Micron's earnings, Biogen's fall, Apple's upcoming event and Elon Musk.
Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.
Jim Cramer has his eyes on Micron's earnings, Biogen's disappointment and Apple's upcoming event.
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
Let's check to see what can be gleaned.
Stocks recoup some losses in late trading but close lower as momentum from a report that China and the U.S. are in the final stages of completing a trade deal fades.
Biogen will purchase Nightstar Therapeutics in an all-cash deal that values the British gene-therapy company at $877 million.
The most recent short interest data has been released for the 01/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
- Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's...
And it is happening not a moment too soon.
Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.
For the month of November RMPIA climbed 1.2% month over month.
Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.
Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.
Jim Cramer weighs in on Colgate-Palmolive, Biogen Idec, Covanta, Cypress Semiconductor, Carrizo Oil & Gas, Allstate and more.
